Lataa...
NQPC-05 BEVACIZUMAB AFTER PROGRESSION OF GLIOBLASTOMA PROLONGS PATIENT’S LIVING TIME AT HOME IN THE LAST 90 DAYS
Bevacizumab (Bev) is currently available for recurrent glioblastoma to improve a patient’s quality of life (QoL). To maintain a patient’s daily life activity, Bev is sometimes continued beyond radiographical progression until neurological deteriorations. However, the benefit of continuous use of Bev...
Tallennettuna:
| Julkaisussa: | Neurooncol Adv |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Oxford University Press
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7213194/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/noajnl/vdz039.136 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|